NCT06297551 Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
| NCT ID | NCT06297551 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Suhu Liu |
| Condition | Acute Myeloid Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-05-17 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2024-05-17 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow and the most common form of acute leukemia in adults. Patient with AML have the shortest survival compared to other forms of leukemia. In the past 6 years, several new therapies have been approved. Biomarkers are in urgent need to guide therapeutic regimen selection in order to maximize the benefit of available therapies and minimize treatment toxicity. Current standard practice is to perform bone marrow biopsy at end of treatment cycle (each cycle around 28 days), and based on bone marrow finding, to decide further treatment plan. It is invasive and time consuming. In this study investigators will study whether tracking leukemia stem cells (LSC) in peripheral blood during early treatment cycle may provide a non-invasive method to predict therapeutic outcome at end of treatment cycle. A retrospective study found that LSC fractional change, defined by two LSC markers, named CLL1 and CD45RA, is highly correlated with therapeutic outcome. Further more, CLL1 and CD45RA positive LSC fraction demonstrates a high concordance between bone marrow and peripheral blood, offering the opportunity to track CLL1 and CD45RA positive LSC fraction non-invasively in peripheral blood during treatment. This pilot study will allow the investigators to decide whether testing CLL1 and CD45RA positive LSC in peripheral blood during leukemia treatment is feasible in clinical practice. This result will lay the foundation for designing future trials using CLL1 and CD45RA positive LSC fractional change to optimize therapeutic strategy for patients with AML.
Eligibility Criteria
Inclusion Criteria: * diagnosis of acute myeloid leukemia * ability to receive treatment for acute myeloid leukemia at the research center * elevated values of CLL1A and CD45RA positive cells at the time of diagnosis
Contact & Investigator
Suhu Liu, MD PhD
PRINCIPAL INVESTIGATOR
Stony Brook Medicine
Frequently Asked Questions
Who can join the NCT06297551 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06297551 currently recruiting?
Yes, NCT06297551 is actively recruiting participants. Contact the research team at cancerclinicaltrials@stonybrookmedicine.edu for enrollment information.
Where is the NCT06297551 trial being conducted?
This trial is being conducted at Stony Brook, United States.
Who is sponsoring the NCT06297551 clinical trial?
NCT06297551 is sponsored by Suhu Liu. The principal investigator is Suhu Liu, MD PhD at Stony Brook Medicine. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.